SGRL
SGRL · NSEValuation
Blended fair value using DCF and peer comparison methods.
See if SGRL is undervalued
Unlock intrinsic value for 4,800+ Indian stocks — free.
Sign in or create free accountThe intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.
Peer comparison
How this company stacks up against sector peers on valuation and quality metrics.
Branded generics & specialty pharma · 8 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
SGRL SGRL · you | ₹871 Cr | 56.4× | 6.5× | — | 11.6% | 0.1% | — |
| Sector median | — | 29.5× | 3.3× | 11.0× | 10.0% | 0.1% | 3.4% |
| RPG Life Sciences Limited RPGLIFE | ₹4,589 Cr | 38.4× | 12.1× | — | 31.5% | 0.2% | — |
| Advanced Enzyme Technologies Limited ADVENZYMES | ₹3,346 Cr | 23.1× | 2.4× | 11.0× | 10.3% | 22.6% | 11.3% |
| Gufic Biosciences Limited GUFICBIO | ₹3,161 Cr | 57.5× | 5.6× | 21.1× | 9.7% | 6.8% | 11.0% |
| Hikal Limited HIKAL | ₹2,625 Cr | — | 2.3× | — | -4.1% | -2.8% | -5.4% |
| Venus Remedies Limited VENUSREM | ₹2,388 Cr | 21.1× | 4.8× | — | 22.9% | 0.1% | — |
| Indoco Remedies Limited INDOCO | ₹2,040 Cr | — | 2.2× | — | -10.1% | -5.2% | 3.4% |
| Windlas Biotech Limited WINDLAS | ₹2,010 Cr | 29.5× | 4.2× | — | 14.1% | 0.1% | — |
| Solara Active Pharma Sciences Limited SOLARA | ₹1,746 Cr | — | 2.2× | 9.9× | -0.6% | -0.5% | -1.8% |
SGRL trades at a premium to sector peers on P/E (55.3× vs median 29.5×). The market is pricing in higher growth — worth verifying whether recent revenue trends support that expectation.
Business quality
Valuation
Returns
Growth
Efficiency
Liquidity & Solvency
Financial health
Piotroski F-Score, Altman Z-Score, and key solvency ratios.
Full financial data
Charts and annual statements for income, balance sheet and cash flow.
Income trend
Revenue, profit and margin trends over time.
Cash flow
Where cash comes from and where it goes.
Balance sheet
Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.